• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

    2/12/24 11:53:37 AM ET
    $ATR
    Plastic Products
    Industrials
    Get the next $ATR alert in real time by email
    SC 13G/A 1 AptargroupIncATR.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.9)* APTARGROUP, INC. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 038336103 ----------------------------------------------------- (CUSIP Number) December 31, 2023 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.038336103 13G Page 2 of 5 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 4,692,291 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 4,783,953 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,798,477 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 7.3% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.038336103 13G Page 3 of 5 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: APTARGROUP, INC. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 265 EXCHANGE DRIVE SUITE 301 CRYSTAL LAKE IL 60014 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 038336103 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.038336103 13G Page 4 of 5 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of December 31, 2023.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.038336103 13G Page 5 of 5 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 12, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY
    Get the next $ATR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATR

    DatePrice TargetRatingAnalyst
    1/7/2025$200.00Outperform
    Raymond James
    1/6/2025$173.00Buy → Neutral
    BofA Securities
    10/14/2024$155.00 → $215.00Hold → Buy
    Jefferies
    4/29/2024Mkt Perform → Outperform
    William Blair
    1/3/2024$125.00 → $150.00Neutral → Outperform
    Robert W. Baird
    1/20/2022$150.00 → $126.00Equal-Weight
    Morgan Stanley
    12/22/2021$162.00 → $156.00Overweight
    Wells Fargo
    12/20/2021$148.00 → $145.00Buy
    Deutsche Bank
    More analyst ratings

    $ATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Glickman Sarah Js was granted 1,069 shares, increasing direct ownership by 53% to 3,076 units (SEC Form 4)

      4 - APTARGROUP, INC. (0000896622) (Issuer)

      5/9/25 9:28:24 AM ET
      $ATR
      Plastic Products
      Industrials
    • Chief Human Resources Officer Vinczeller Shiela sold $151,658 worth of shares (995 units at $152.42), decreasing direct ownership by 4% to 26,301 units (SEC Form 4)

      4 - APTARGROUP, INC. (0000896622) (Issuer)

      5/8/25 5:35:08 PM ET
      $ATR
      Plastic Products
      Industrials
    • Director Owens B Craig was granted 1,069 shares, increasing direct ownership by 12% to 9,757 units (SEC Form 4)

      4 - APTARGROUP, INC. (0000896622) (Issuer)

      5/8/25 5:29:42 PM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on AptarGroup with a new price target

      Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00

      1/7/25 9:09:40 AM ET
      $ATR
      Plastic Products
      Industrials
    • AptarGroup downgraded by BofA Securities with a new price target

      BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00

      1/6/25 9:13:43 AM ET
      $ATR
      Plastic Products
      Industrials
    • AptarGroup upgraded by Jefferies with a new price target

      Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously

      10/14/24 7:25:09 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptar Reports First Quarter 2025 Results

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill

      5/1/25 5:03:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Declares Quarterly Dividend

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar

      4/17/25 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers

      SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform. The platform was developed by Aptar's drug services company, Nanopharm. If validated, SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes – removing a major barrier for pharma companies and regulators and paving the way for wider patient access to medications. This validation would estab

      4/16/25 8:00:00 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Aptar CFO, Robert (Bob) Kuhn, Has Decided to Step Down After 37 Years with the Company

      Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,

      7/25/24 5:20:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Appoints Global Finance and Operations Veteran Sarah Glickman to its Board of Directors

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry

      9/5/23 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Appoints Julie Xing to its Board of Directors

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g

      3/1/23 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    SEC Filings

    See more
    • SEC Form SD filed by AptarGroup Inc.

      SD - APTARGROUP, INC. (0000896622) (Filer)

      5/16/25 9:27:34 AM ET
      $ATR
      Plastic Products
      Industrials
    • SEC Form S-8 filed by AptarGroup Inc.

      S-8 - APTARGROUP, INC. (0000896622) (Filer)

      5/9/25 4:12:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • AptarGroup Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - APTARGROUP, INC. (0000896622) (Filer)

      5/8/25 9:02:00 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

      SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

      2/13/24 4:58:57 PM ET
      $ATR
      Plastic Products
      Industrials
    • SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

      SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

      2/12/24 3:08:10 PM ET
      $ATR
      Plastic Products
      Industrials
    • SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

      SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

      2/12/24 11:53:37 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Financials

    Live finance-specific insights

    See more
    • Aptar Reports First Quarter 2025 Results

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill

      5/1/25 5:03:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Declares Quarterly Dividend

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar

      4/17/25 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Reports Fourth Quarter and Annual 2024 Results

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top and bottom line improvements. Results were driven by sales growth in pharma solutions, increased demand for closures technologies and productivity gains across the company. Reported sales increased by 1% and core sales increased by 2% due to a negative currency effect. Aptar reported net income of $101 million for the quarter, a 62% increase from the prior year. In addition, the quarterly results benefited from a lower effective tax rate. This press release features multimedi

      2/6/25 5:17:00 PM ET
      $ATR
      Plastic Products
      Industrials